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Induced pluripotent stem cells (iPSC) constitute a powerful tool to study cardiac physiology and represents a promising treatment
strategy to tackle cardiac disease. However, iPSCs remain relatively immature after differentiation. Additionally, engineered heart
tissue (EHT) has been investigated as a therapy option in preclinical disease models with promising results, although their
vascularization and functionality leave room for improvement. Thymosin 𝛽4 (T𝛽4) has been shown to promote the differentiation
of progenitor cell lines to cardiomyocytes while it also induces angiogenic sprouting and vascular maturation. We examined the
potential impact of T𝛽4 to enhance maturation of cardiomyocytes from iPSCs. Assessing the expression of transcription factors
associated with cardiac differentiation, we were able to demonstrate the increased generation of cells displaying cardiomyocyte
characteristics in vitro. Furthermore, we demonstrated, in a zebrafish model of embryonic vascular development, that T𝛽4 is
crucial for the proper execution of lymphatic and angiogenic vessel sprouting. Finally, utilizing T𝛽4-transduced EHTs generated
frommice genetically engineered to label endothelial cells in vitro, we show that treatment with T𝛽4 promotes vascularization and
contractility in EHTs, highlighting T𝛽4 as a growth factor improving the formation of cardiomyocytes from iPSC and enhancing
the performance of EHTs generated from neonatal cardiomyocytes.
1. Introduction
Engineered heart tissue generated from neonatal cardiomy-
ocytes has been a useful tool to study cardiac physiology
and presents a promising treatment option for patients
with heart failure or excessive scar tissue formation after
myocardial infarction, which has been demonstrated in
preclinical animalmodels ofmyocardial replacement therapy
[1, 2]. However, major obstacles in generating functioning
EHT-grafts of sufficient size still remain. For instance, while
grafts can generate primitive vascular networks [3], those
vessels typically are unable to support EHTs of increasing
thickness [4]. Additionally, myocardial-grafts derived from
neonatal cardiomyocytes lack the level of maturity seen in
adult myocardium. On the one hand, those EHTs do display
features of fully matured, adult cardiomyocytes, such as the
expression of contractile proteins, their organization into
sarcomeric structures, and the capability to mimic basic
cardiomyocyte physiology [5–7]. However, thusly generated
engineered heart tissue grafts still have a higher ratio of fetal
myosin heavy chain and are unable to generate comparable
force [8], which reflects their relative immaturity.
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Thymosin 𝛽4 (T𝛽4), although first described as a G-actin
sequestering peptide regulating cytoskeletal rearrangement
and cellular motility [9], has recently been shown to pos-
sess additional functions during cell fate determination and
angiogenesis. Thus, it was demonstrated that T𝛽4 in mouse
models of myocardial ischemia promotes the proliferation of
mesenchymal stem cells, improving cardiac function [9], and
advances the transdifferentiation of epicardial progenitors
into integrated cardiomyocytes [10]. Furthermore, T𝛽4 was
shown to facilitate angiogenic sprouting, by activating SRF
target genes via the nuclear translocation of MRTF-A [11],
and to foster the attachment of mural cells to endothelial cell
tubes, improving the functionality of vessels [12, 13].
On account of Thymosin 𝛽4 promoting cardiomyocyte
differentiation and improving tissue supply with functioning
vasculature, we investigated the effect of T𝛽4 on the differ-
entiation of iPSCs to myocardial cells and its impact on the
quality of engineered heart tissues.
2. Materials and Methods
2.1. Generation of Induced Pluripotent Stem Cells. Induced
pluripotent stem cells derived from murine embryonic
fibroblasts were kindly provided by Ulrich Martin [14].
Cells were cultured on mitotically inactivated murine
embryonic fibroblasts (MEFs; 50 000 cells/cm2) in 6-well
plates. The culture medium was composed of Dulbecco’s
modified Eagle’s medium (Invitrogen, Carlsbad, Calif)
with 15% fetal calf serum (Thermo Fisher Scientific Ger-
many), 0.2mmol/L l-glutamine (Invitrogen), 0.1mmol/L
𝛽-mercaptoethanol (Invitrogen), 0.1mmol/L nonessential
amino acid stock (Invitrogen), and 0.1% human leukemia
inhibitory factor-conditioned medium, which had been
produced by transient transfection of a human leukemia
inhibitory factor expression plasmid into human embry-
onic kidney 293 cells. To initiate embryoid body forma-
tion, cells were cultured in the “hanging drop” technique
with 600 cells/20𝜇L of differentiation medium, consisting
of Iscove’s modified Dulbecco’s medium with 15% FCS,
0.2mmol/L l-glutamine, 0.1mmol/L 𝛽-mercaptoethanol, and
0.1mmol/L nonessential amino acid stock. After 3 days of
differentiation EBs were transferred onto nonadherent 1%
agarose-coated 96-wells, followed by a transfer of 10 EBs per
well on a 0.1% gelatin-coated 6-well culture dish.
2.2. Vascular Patterning in Zebrafish. Embryos and adult
zebrafish were raised and maintained under standard condi-
tions.The transgenic zebrafish line Tg(fli1a:EGFP)y1 was used
as previously described [15]. Morpholinos, used to knock-
down tmsb-like expression and control morpholinos, were
injected into embryos at the 1 to 2 cell stage (15 ng/embryo).
Thedeveloping vasculaturewas examined using the Leica SP5
confocal microscope.
2.3. Flow Cytometry. Induced pluripotent stem cells were
trypsinized, washed in cold PBS, and fixed for 20 minutes
at RT in 3.7% formaldehyde. Cells were permeabilized with
0.4% Triton X-100 in PBS and subsequently incubated with
antibodies as indicated for 2 hours at 37∘C in 0.4% Triton X-
100 in PBS. Stainings were performed with antibodies against
cardiac Troponin I (BD Pharmingen, San Diego, US), 𝛼MHC
(BD Pharmingen, San Diego, US), and 𝛼-actinin (Sigma
Aldrich, St. Louis, US). A FITC conjugated IgG antibody
served as a control. After washing, cells were analyzed
on a Coulter Epics XL-MCLTM flow cytometer (Beckman
Coulter, Krefeld, Germany).
2.4. Quantitative Real-Time PCR. RNA from iPSCs was
isolated at timepoints indicated and reverse-transcribed into
cDNA. qPCR was performed on a iQ-cycler (Bio-Rad,
Munich, Germany) with SYBR-Green Supermix (Bio-Rad,
Munich, Germany). For qPCR, the following primers were
used: Brachyury (T): upper: 5󸀠 ACCCAGCTCTAAGGA-
ACCAC 3󸀠; lower: 5󸀠 ACTCCGAGGCTAGACCAGTT 3󸀠;
Eomes: upper: 5󸀠 CTCTAGACTCCAGCGACTCC 3󸀠; lower:
5󸀠 GCCTTTGGAGGTGTCTTTAC 3󸀠; Mesp1: upper: 5󸀠
CAGTACGCAGAAACAGCATC 3󸀠; lower: 5󸀠 GGTTTC-
TAGAAGAGCCAGCA 3󸀠; NKX-2.5: upper: 5󸀠 CATTTA-
CCCGGGAGCCTACG 3󸀠; lower: 5󸀠GCTTTCCGTCGC-
CGCCGTGC 3󸀠; ANF: upper: 5󸀠 GCAAATCCTGTGTAC-
AGTGC 3󸀠; lower: 5󸀠 CAGGTGGTCTAGCAGGTTCT 3󸀠;
CX43: upper: 5󸀠 CTGTCGGTGCTCTTCATTTTC 3󸀠; lower:
5󸀠 GTGGGCACAGACACGAATATG 3󸀠.
2.5. Generation of EHTs. Neonatal mouse heart cells were
isolated from Cdh5-CreERT2 × Rosa26-LacZ mice, express-
ing LacZ in endothelial cells as described previously [16].
Cells were mixed with fibrinogen (1mg/mL, Sigma, F4753),
medium (DMEM), Matrigel (100 𝜇L/mL, BD Bioscience,
356235), and thrombin (100U/mL, Sigma, T7513) and sub-
sequently casted into strip-format molds in agarose (dimen-
sions 12 × 3 × 3mm) with pairs of elastic silicone posts
placed from above. After fibrinogen polymerization (2 hours,
37∘C, 7% CO2), mold racks were transferred to a new 24-
well plate and EHTs were cultured with DMEM (Biochrom
F0415), supplemented with 10% horse serum (Gibco 26050),
2% chick embryo extract, 1% penicillin/streptomycin (Gibco
15140), insulin (10𝜇g/mL, Sigma I9278), tranexamic acid
(400 𝜇mol/L, Sigma 857653), and aprotinin (33 𝜇g/mL, Sigma
A1153).
2.6. Skinfold Chamber. BALB/c nude mice were anaes-
thetized with an intraperitoneal injection of midazolam,
medetomidine, and fentanyl and placed on a warming
platform. After hair removal and fixation of the back skin
via silk sutures, two openings at the base of the skinfold
were prepared through which the connecting screws of the
chamber were passed. The observation window was marked
and one skin layer was removed. Subsequently, the previously
generated EHT-grafts were sutured into the observation
window and sealed with a cover glass kept in place by a snap
ring. After fixing the second half of the chamber, anaesthesia
was antagonized with atipamezole, flumazenil, and naloxone
and mice were placed in individual cages until further use.
For imaging of angiogenic sprouting derived from the EHT-
grafts, whole mount X-Gal staining from Cdh5-CreERT2 ×
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Rosa26-LacZ derived EHTs was performed and subsequently
imaged via light microscopy.
2.7. Statistical Analysis. Data are given as mean ± SEM.
Differences among several groups were tested using ANOVA
and the Student Newman Keuls post hoc analysis. A 𝑝 value
of < 0.05 was considered statistically significant. All data
were assessed using the SPSS software package (version 20.0;
http://www.spss.com). Sample sizes are provided in the figure
legends.
3. Results and Discussion
3.1. Thymosin 𝛽4 Drives Cardiac Differentiation in Induced
Pluripotent Stem Cells. To investigate the potential of Thy-
mosin 𝛽4 (T𝛽4) to induce cardiac differentiation in murine
induced pluripotent stem cells (iPSC), we analyzed differ-
ences in the expression of a variety of transcription factors
and cardiac markers at different timepoints during treatment
of iPSCs with T𝛽4 (Figure 1(a)). We found that during early
stages of differentiation (day 4) T𝛽4 significantly increased
the expression of mRNA encoding the T-Bos-transcription
factors Eomesodermin (Eomes) and Brachyury (T), which
are indispensable for mesoderm formation in general and
are known to be early mesoderm markers [17, 18] (Figures
1(b) and 1(c)). Apart from promoting the formation of
early mesoderm, a treatment with T𝛽4 also enhanced the
expression of MesP1, the earliest marker of cardiovascular
progenitors [19, 20], and NKX-2.5, which has been shown
to be crucial for cardiac development [21] (Figures 1(d)
and 1(e)). Similar results for the expression of MesP1 and
NKX-2.5 were observed in T𝛽4 treated GSES embryonic
stem cells (data not shown). Finally, T𝛽4 treatment after
differentiation for 6 days was able to significantly increase the
expression of the myocardial proteins atrial natriuretic factor
(ANF) and connexin 43 (CX43) and the production of the
cardiac specific proteins alpha myosin heavy chain (𝛼MHC),
Troponin, and 𝛼-actinin (Figures 1(f)–1(h)). The increased
expression of contractile cardiac proteins in iPSCs via the
treatment of those cells with T𝛽4 resulted in a dramatic
increase in contracting cardiomyocytes compared to control
(Figure 1(i)).
The mode of action of T𝛽4 comprises two separate
physiological processes: first, T𝛽4 binds monomeric G-actin,
preventing it from forming or joining actin filaments via
profilin, which, upon binding, favors the incorporation of
actin into filaments [22]. Secondly, T𝛽4 can regulate the
expression of a number of serum response factor (SRF) target
genes. This effect depends on the nuclear translocation of the
myocardin-related transcription factor A (MRTF-A), also a
G-actin binding protein [23]. An increase in actin binding
to T𝛽4 frees actin-bound MRTF-A leading to its nuclear
translocation and SRF-binding [24, 25]. Inside the nucleus,
MRTF-A acts as a transcriptional coactivator physically asso-
ciating with SRF [26]. Interestingly, SRF signaling appears
to be indispensable for mesoderm formation. SRF-deficient
mice die during early embryonic development starting from
E9.5 with impaired gastrulation and a lack of mesodermal
cells [27]. Furthermore, embryonic stem cells lacking SRF
are incapable of driving Brachyury (T) expression upon
induction of differentiation [28]. Additionally, Nam et al.
demonstrated that MRTF-A is a potent inducer of car-
diac protein expression during the reprograming of human
foreskin fibroblasts, increasing the amount of fibroblasts
expressing cardiac troponin from 0,2% (2%) to 17% (13%)
during GMT (or GHMT) induced cardiac differentiation
[29]. Additionally,Thymosin𝛽4 is well known to promote the
differentiation of embryonic stem cells [30] and drive fibrob-
last to cardiomyocyte differentiation inmodels of myocardial
ischemia [31]. Furthermore, Thymosin 𝛽4 has been shown
to promote proliferation and reduce apoptosis under stress-
conditions in mesenchymal stem cells [9], highlighting the
possibility that T𝛽4 might increase the pool of stem cells
differentiating via proliferation and by shielding them from
apoptosis. These findings point to the possibility that T𝛽4
facilitates the differentiation of iPSCs to cardiomyocytes
either by directly inducing differentiation, by increasing the
abundance of mesodermal progenitors, which subsequently
differentiate independent of T𝛽4, or by protecting iPSCs
during differentiation.
3.2. Inhibition of Thymosin 𝛽4 Induces Lymphatic Abnor-
malities in Zebrafish. To investigate the role of T𝛽4 during
development in zebrafish, we first sought to identify which
possible T𝛽4 isoform in zebrafish corresponds to the human
and mouse isoforms. To this end, the amino acid sequences
of T𝛽4 from human and mouse were aligned with the
zebrafish orthologs beta Thymosin and beta Thymosin-like
(Figure 2(a)). Aligning these sequences demonstrated a closer
homology of the consensus actin binding sequence [32]
of beta Thymosin-like to the mammalian Thymosins than
that of zebrafish beta Thymosin. Additionally, the genomic
localization in regard to its proximity to tlr7 and egfl6 of
tmsb-like more closely resembles that of murine and human
Thymosin 𝛽4, as demonstrated in Figure 2(b). For these
reasons, we assessed the effect of a morpholino mediated
knockdown of beta Thymosin-like rather than beta Thy-
mosin. Before evaluating the effect of tmsb-like morpholino
mediated knockdown on vascular development, zebrafish
embryos were microinjected with GFP-tagged tmsb-like in
the presence or absence of tmsb-like morpholinos (tmsb-
like-MO, Figure 2(c)) to investigate knockdown efficiency.
This led to a clear expression of the GFP-tagged protein,
while additional injection with tmsb-like-MO blunted the
expression of GFP-tmsb-like, indicating the efficiency of our
morpholino mediated Thymosin beta like knockdown (Fig-
ure 2(d)). The tmsb-like morpholinos and control morpholi-
nos were subsequently injected into Tg(fli1.egfp)y1 transgenic
zebrafish, which express enhanced GFP under the control
of the fli1 promoter in the entire vasculature to assess the
embryonic development of the vasculature and lymphatic
system [33].
In investigating morpholino treated zebrafish at day 5.5
postfertilization (dpf), varying degrees of edema forma-
tion were apparent in tmsb-like-MO treated animals while
formation of edema was virtually absent in control-MO
treated zebrafish (tmsb-like-MOwith moderate edema: 40%,
sever edema: 37%, Figures 3(a) and 3(b)). Since excessive
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Figure 1: Thymosin 𝛽4 promotes the generation of cardiomyocytes from murine induced pluripotent stem cells. (a) Undifferentiated iPSCs
were treatedwith T𝛽4-peptide and expression of transcription factor encodingmRNAswasmeasured 4 (Eomes, Brachyury (T)), 6 (Mesp1), or
8 (NKX-2.5) days after T𝛽4 treatment (red). In another approach, murine iPSCs were differentiated for 6 days and treated with T𝛽4-peptide. 8
days after T𝛽4 treatment, expression levels of cardiomyocyte markers (ANF, CX43) were measured and flow cytometric assessment of cardiac
specific proteins (𝛼MHC, Troponin, and 𝛼-actinin) was performed. Furthermore, the amount of beating areas was measured (blue). (b–g)
Relative expression levels of transcripts as indicated ((b–e) without prior differentiation of iPSCs, (f and g) with 6 days of prior differentiation),
measured via quantitative real-time PCR, reveal that T𝛽4 induces the expression of transcription factors regulating the differentiation of stem
cells to cardiomyocytes via mesenchymal and cardiac progenitor stages and the expression of cardiac specific transcripts. (h) Flow cytometry
after intracellular staining for 𝛼MHC, Troponin, and 𝛼-actinin reveals the increased presence of these cardiac specific proteins after T𝛽4
stimulation. (i) T𝛽4 treated iPSCs show a high rate of spontaneous beating compared to untreated iPSCs in which beating was virtually
absent. (𝑛 = 3, ∗𝑝 < 0.05).
edema formation is associated with malformation of the
lymphatic system and defective thoracic duct formation (TD)
[34–36], we investigated if a tmsb-like knockdown impairs
the thoracic duct development by assessing its presence
in 10 somites. These results revealed that, in tmsb-like-
MO treated animals, TD formation was severely impaired
at 5.5 dpf with no animals displaying TD formation in all
somites and 68% showing no duct formation at all, whereas
in control-MO treated animals 96% showed proper TD
formation (Figures 3(c) and 3(d)). Since the thoracic duct is
preceded by the emergence of parachordal lymphatic vessels
(PC) that start to sprout from the embryonic posterior
cardinal vein (PCV) at around 32 hours postfertilization
(hpf) [37, 38], we investigated the influence of a tmsb-like
KD on the pattern of PC-formation at 60 hpf by in vivo
confocal imaging of Tg(fli1-egfp)y1 zebrafish. At this stage,
the already formed main vessels (dorsal aorta (DA) and
posterior cardinal vein (PCV)), which form approximately at
1 dpf [39], displayed no apparent phenotype. Intersegmental
vessels (ISV) and the dorsal longitudinal anastomotic vessels
(DLAV), however, seemed disorganized and displayed a
hypersprouting phenotype in tmsb-like-MO treated animals
compared to control (Figures 3(e) and 3(g)). Furthermore,
PC-development was severely impaired as demonstrated by a
reduction in parachordal lymphangioblast carrying somites
(Figures 3(e) and 3(f)). The role of T𝛽4 in lymphatic vessel
development remains poorly understood, while the effect of
T𝛽4 on blood vessel maturation has been studied intensively
in recent years, demonstrating the potent stabilizing effect
of T𝛽4 on newly formed vessels. To this end it has been
shown that T𝛽4, apart from inducing angiogenic sprouting
via the activation of CCN1 [40], promotes the recruitment
of mural cells (pericytes in particular) to the vasculature via
the activation of MRTF-A and the downstream induction of
the SRF target gene CCN2 [41]. Thus, the disorganization
of the intersegmental vessels and the dorsal longitudinal
vessels may be based on the absence of stabilizing mural
cells. The hypothesis of increasing vascular destabilization
in the absence of tmsb-like was further supported by the
observation that tmsb-like-MO treated animals suffered from
a high rate of cerebral vascular hemorrhages, a hallmark of
instable vessels due to the lack of mural cells [42], while
hemorrhage in control-MO treated animals was rarely seen,
pointing at the presence of unstable vessels in tmsb-like-MO
animals (Figures 3(h) and 3(i)). Similar phenotypic changes,
an increase in vascular hemorrhage due to a reduction
in mural cell coverage, have been demonstrated in mouse
models of T𝛽4 deficiency, indicating the importance of T𝛽4
in the proper vascular development throughout vertebrate
species [13]. In the case of the lymphatic system, the incom-
petence in lymphatic vessel sprouting seen in tmsb-like-
MO zebrafish may be due to the unregulated assembly and
disassembly of filamentous actin necessary for cell migration
in embryonic lymphangioblasts. Another possibility is that
the mechanism of sprouting and vessel maturation mediated
by tmsb-like is similar in lymphatic vessels or that the
deficiency in parachordal lymphangioblast sprouting stems
from the disorder of ISV which are necessary guidance cues
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Figure 2: Identification of a Thymosin 𝛽4 ortholog in zebrafish. (a) Amino acid sequence alignment of zebrafish beta Thymosin and beta
Thymosin-like andmouse and humanThymosin 𝛽4.The yellow box indicates the consensus actin bindingmotif, indicating a closer degree of
homology of zebrafish betaThymosin-like to themammalianThymosins than betaThymosin. (b)The comparison of the genomic localization
of beta Thymosin and beta Thymosin-like in zebrafish, in relation to the murine and human localization, shows a closer proximity of beta
Thymosin-like than beta Thymosin to the mammalian Thymosin 𝛽4. (c) Vector used to integrate pEGFP-N1-tmsb-like in zebrafish with
indicated binding site of tmsb-like morpholinos (tmsb-like-MO) used to knockdown tmsb-like in zebrafish. (d) Treatment of pEGFP-N1-
tmsb-like expressing zebrafish embryos with tmsb-like-MO demonstrates high knockdown efficiency.
for lymphangioblast migration from the posterior cardinal
vein [37].
3.3. Treatment of Engineered Heart Tissue with T𝛽4 Improves
Vascularization and Contractility. Having demonstrated that
treatment of iPSCs with T𝛽4 increases the abundance of
functional cardiomyocytes and knowing that T𝛽4 promotes
vascular stability and is necessary for proper angiogenetic
sprouting, we sought to investigate if a treatment of engi-
neered heart tissue (EHT) from murine heart cells with T𝛽4
promotes the vascularization of these tissue grafts. To this
end, EHTs were generated from neonatal mouse heart cells
of Cdh5-CreERT2 × Rosa26-LacZ mice, expressing LacZ
in endothelial cells, and treated with T𝛽4-peptide. Initially,
cross sections of EHTs revealed a significantly higher capil-
lary density if treated with T𝛽4 (Figure 4(a)) and displayed
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Figure 3: Effect of morpholino mediated tmsb-like knockdown in zebrafish. (a) Edema formation in zebrafish treated with tmsb-like-MO.
Knockdown animals show moderate (a󸀠) to severe (a󸀠󸀠) edema formation compared to control ((a), arrowhead), which was quantified in
(b) (𝑛 = 123 for control-MO and 114 for tmsb-like-MO). (c) Thoracic duct (TD) formation was blunted to a moderate (c󸀠) to sever (c󸀠󸀠)
degree in tmsb-like-MO animals compared to proper TD formation in control animals 5.5 days postfertilization (dpf, (c), arrowhead).
Results were quantified in (d) (𝑛 = 112 for control-MO and 103 for tmsb-like-MO). (e) Knockdown of tmsb-like leads to the aberrant
formation of intersegmental vessels (ISV) displaying an ineffective hypersprouting phenotype (arrowheads) and a perturbation of parachordal
lymphatic vessel generation by parachordal lymphangioblasts (PL) 60 hpf. (PCV: posterior cardinal vein, DA: dorsal aorta, and DLAV: dorsal
longitudinal anastomotic vessel). (f) Presence of parachordal lymphangioblasts in 10 successive somites (𝑛 = 109 for control-MO and 118 for
tmsb-like-MO) and (g) average number of ectopic ISV branch points in 5 bilateral ISV (𝑛 = 55 per group, ∗𝑝 < 0.05) demonstrate excessive
branching and ineffective parachordal vessel formation in animals lacking tmsb-like. (h and i) tmsb-like-MO treated animals displayed a high
rate of cerebral vascular hemorrhage compared to control-treated animals 60 hours postfertilization (𝑛 = 225 for control-MO and 204 for
tmsb-like-MO, ∗𝑝 < 0.05).
an increase in contractile force (data not shown). Subse-
quently, EHTs were implanted into skinfold chambers in
mice. Already macroscopically, T𝛽4 treated, implanted EHTs
showed a dramatic increase in vascularization (Figure 4(b)),
which was confirmed by quantifying the vessels per quadrant
of those EHTs 5 days after implantation (ctrl.: 8.4 ± 1.9, T𝛽4
14.8 ± 1 vessels/quadrant) which became even more promi-
nent 8 days after implantation (ctrl.: 6.4 ± 0.8, T𝛽4 24.5 ± 2.4
vessels/quadrant, Figures 4(b) and 4(c)). In addition, intra-
venous injection of FITC-dextran demonstrated that these
vessels are perfused, highlighting the functionality of these
vessels (Supplementary Movie 1 in Supplementary Material
available online at https://doi.org/10.1155/2017/6848271). To
investigate the origin of these new vessels, we implanted
EHTs from Cdh5-CreERT2 × Rosa26-LacZ mice after T𝛽4
or control treatment and observed, after 𝛽-galactosidase
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Figure 4: Increased vascularization and contractility in engineered heart tissue under Thymosin 𝛽4 treatment. (a) Cross sections of EHTs
from reporter mice expressing LacZ in endothelial cells (Cdh5-CreERT2 ×Rosa26-LacZ) reveal an increase in capillary density if treated with
T𝛽4. (b and c) AAV-mediated transfection with T𝛽4 (rAAV.T𝛽4, versus rAAV.GFP as control) of EHTs implanted into skinfold chambers
leads to an increase of graft-vascularization, both 5 and 8 days after implantation (𝑛 = 4 per group, ∗𝑝 < 0.05; ∗∗𝑝 < 0.0008). (d) Images of
whole skinfold chambers containing EHTs generated from LacZ reportermice show little sprouting of graft resident endothelial cells into host
tissue, while rAAV.T𝛽4 treatment drastically induces angiogenic sprouting into the host tissue of skinfold chambers (dotted lines indicate the
graft/host border). (e) Treatment with rAAV.T𝛽4 leads to an increase of spontaneous contractions in implanted EHTs compared to rAAV.GFP
control (𝑛 = 4 per group, ∗𝑝 < 0.05).
staining, that the newly formed vasculature had its origin
predominantly in the EHTs sprouting to the surrounding
tissue of the skinfold chamber (Figure 4(d)). Lastly, to inves-
tigate the functionality of the implanted grafts, the amount of
contractions was assessed and revealed a dramatic increase in
the number of contractions per minute in T𝛽4 treated EHTs
(Figure 4(e)). Taken together, these findings implicate that the
vascularization and performance of EHT can be improved
by the treatment of EHTs with T𝛽4. As with our results
regarding iPSCs, this effect might be attributed to an increase
in the fidelity of neonatal mouse cardiomyocytes during
EHT production, possibly due to a decrease in apoptosis
and an increase in survival, a mechanism which has been
demonstrated in previouswork fromour group in the context
of neonatal rat cardiomyocytes [43].
Combining the findings from our experiments regarding
induced pluripotent stem cells and zebrafish, our results
implicate that T𝛽4 promotes the expansion of mesodermal
progenitors, which subsequently differentiate into blood and
lymphatic vessels. Those, in turn, increase the perfusion and
maintenance of our EHTs. T𝛽4 additionally might stabilize
the cardiomyocyte phenotype of neonatal cardiomyocytes
during EHT-generation by promoting the expression of
cardiac proteins. Another possible mechanism, by which
T𝛽4 enhances EHT functionality, might be by generally
promoting proliferation and inhibiting apoptosis, rendering
EHTs more stable during their assembly and subsequent
implantation.
4. Conclusion
Here we demonstrate that T𝛽4 significantly increases the
amount of cardiomyocyte-like cells differentiated from
Stem Cells International 9
induced pluripotent stem cells and their respective pro-
genitors (mesodermal cells, cardiogenic progenitors, and
cardiac precursors) and that T𝛽4 is required for proper
embryonic development of lymphatic vessels. Furthermore,
T𝛽4 improves vascularization and beating capacity of EHT
generated from neonatal heart cells, possibly by promoting
overall proliferation, protecting from apoptosis, and inducing
angiogenesis and lymphangiogenesis.These results introduce
T𝛽4 as a potential driver of iPSC-differentiation and EHT
vascularization, improving the efficiency of generating EHTs
for further preclinical and clinical use.
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